Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6422
    -0.0004 (-0.05%)
     

  • OIL

    82.63
    -0.10 (-0.12%)
     

  • GOLD

    2,396.40
    -1.60 (-0.07%)
     

  • Bitcoin AUD

    101,157.40
    +3,341.80 (+3.42%)
     

  • CMC Crypto 200

    1,384.34
    +71.71 (+5.78%)
     

  • AUD/EUR

    0.6019
    -0.0011 (-0.19%)
     

  • AUD/NZD

    1.0892
    +0.0017 (+0.15%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,308.85
    -85.46 (-0.49%)
     

  • FTSE

    7,855.09
    -21.96 (-0.28%)
     

  • Dow Jones

    37,944.33
    +168.95 (+0.45%)
     

  • DAX

    17,764.88
    -72.52 (-0.41%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Kiniksa Pharmaceuticals, Ltd.
·1-min read

HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com